• Explore /
  • Poster
  • / Comprehensive genomic and transcriptomic profiling (CGTP) to predict pembrolizumab (P) benefit in patients (pts) with advanced solid tumors (STs).

Comprehensive genomic and transcriptomic profiling (CGTP) to predict pembrolizumab (P) benefit in patients (pts) with advanced solid tumors (STs).

Abstract Video & Slides Poster

Authors

null

Dan Rhodes

Strata Oncology, Ann Arbor, NC

Dan Rhodes , Daniel H Hovelson , Malek M. Safa , Mark E. Burkard , Eddy Shih-Hsin Yang , William Jeffery Edenfield , Travis Reeder , Hana Vakil , Kat Kwiatkowski , Khalis Mitchell , Bryan Johnson , Scott A. Tomlins

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Tissue-Based Biomarkers

Clinical Trial Registration Number

NCT03061305

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 2609)

DOI

10.1200/JCO.2021.39.15_suppl.2609

Abstract #

2609

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Biagio Ricciuti

First Author: Panpan Zhang

First Author: Sandra Jones

First Author: Benjamin Maurice Solomon